STROBE Statement—checklist of items that should be included in reports of observational studies

Section/Item	Item No	Recommendation	Reported on Page Nuber/Line Number	Reported on Section/Paragraph
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	page 1; line 1-2	Title page/Para 1
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	page 2; line 2-18, page 3; line1-5-	Abstract/Para 1-4
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	page 4; line 2-18, page 5; line 1-18, page 6; line 1	Introduction/Para 1-3
Objectives	3	State specific objectives, including any prespecified hypotheses	page 6; line 2-4	Introduction/Para 4
Methods				
Study design	4	Present key elements of study design early in the paper	page 7; line 3-6	Materials and methods/Para 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	page 7; line 7-12	Materials and methods/Para 1
Participants	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants	*(a)* page 7; line 14-18	Materials and methods/Para 1
		(*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case	N/A; This study was not a matched study.	N/A; This study was not a matched study.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	page 8; 1-18, page 9; 1-18, page 10; 1-2	Materials and methods/Para 2-4

Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	page 7; line 16-18, page 8; line 1-18, page 9; line 1-18, page 10; line 1-3	Materials and methods/Para 1-4
Bias	9	Describe any efforts to address potential sources of bias	page 8; line 16-17	Materials and methods/Para 1-3
Study size	10	Explain how the study size was arrived at	N/A; Predetermination of study size was not needed for this study.	N/A; Predetermination of study size was not needed for this study.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	page 8; line 11-18, page 9; line 1-18, page 10; line 1-3	Materials and methods/Para 3-4
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	page 10; line 4-17	Materials and methods/Para 5
		(*b*) Describe any methods used to examine subgroups and interactions	page 10; line 4-17	Materials and methods/Para 5
		(*c*) Explain how missing data were addressed	N/A, There were no missing data in this study.	N/A, There were no missing data in this study.
		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy	*(d)* N/A, There were no missing data in this study.	*(d)* N/A, There were no missing data in this study.
		(*e*) Describe any sensitivity analyses	N/A, There were no sensitivity analyses in this study.	N/A, There were no sensitivity analyses in this study.

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	page 7; line 7-18, page 8; line 1, Table 1	Materials and methods/Para 1
		(b) Give reasons for non-participation at each stage	N/A; There was no non-participation patient in this study.	N/A; There was no non-participation patient in this study.
		(c) Consider use of a flow diagram	N/A; The criteria for patients were simple. No need for a flow diagram.	N/A; The criteria for patients were simple. No need for a flow diagram.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	page 7; line 7-18, page 8; line 1, Table 1	Materials and methods/Para 1
		(b) Indicate number of participants with missing data for each variable of interest	N/A, There were no missing data in this study.	N/A, There were no missing data in this study.
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)	N/A, No need for follow-up time for this study.	N/A, No need for follow-up time for this study.
Outcome data	15*	*Cohort study*—Report numbers of outcome events or summary measures over time	N/A; No outcome data were required for this study.	N/A; No outcome data were required for this study.
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A; This study was not a case-control study.	N/A; This study was not a case-control study.
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A; This study was not a cross-sectional study.	N/A; This study was not a cross-sectional study.
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A; This study did not include the results listed on the left.	N/A; This study did not include the results listed on the left.

		(*b*) Report category boundaries when continuous variables were categorized	page 11; line 1-18, page 12; line 1-18, page 13; line 1-6	Results/Para 1-3
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A; This study did not include the results listed on the left.	N/A; This study did not include the results listed on the left.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A; This study did not include the results listed on the left.	N/A; This study did not include the results listed on the left.
Discussion				
Key results	18	Summarise key results with reference to study objectives	page 16; line 3-6	Discussion/Para 5
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	page 15; line 16-18, page 16; line 1-2	Discussion/Para 4
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	page 14; line 11-18, page 15; line 1-18, page 16; line 1-2	Discussion/Para 2-4
Generalisability	21	Discuss the generalisability (external validity) of the study results	page 15; line 4-15	Discussion/Para 3
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	page 17; line 1	Acknowledgements/Para 1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: http://dx.doi.org/10.21037/gs-20-485.
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.